TOPEX Sells Skin Cancer Business Operations to SENSUS Healthcare
DANBURY, Conn., Aug. 18 /PRNewswire/ -- TOPEX, Inc. announces the sale of its skin cancer business operations to SENSUS Healthcare, LLC for its low energy SRT 100 superficial radiotherapy treatment system. Since TOPEX received FDA approval during 2007, many systems have been operating worldwide at hospital radiation oncology centers, dermatology and veterinary oncology practices for the treatment of skin cancer. The low energy superficial radiotherapy system provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, especially primary lesions requiring difficult or extensive surgery with sensitive structures in the head and neck regions -- the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear that would otherwise lead to a less than desirable cosmetic outcome. This treatment procedure does not require the use of anesthetics and eliminates the need for skin grafting.
Anthony Pellegrino, TOPEX founder and CEO, stated, "SENSUS Healthcare brings together a highly skilled team of technical sales and marketing professionals for expanding superficial radiotherapy clinical use and business development in the global marketplace."
Joe Sardano, CEO, SENSUS Healthcare stated, "Mr. Pellegrino is recognized for making good technologies better. Physicians and patients alike deserve to have better choices for their treatment. Superficial Radiotherapy provides a non invasive choice to treat skin cancer with appropriate dose levels and proven clinical high cure rates. SENSUS is privileged to offer this technology as well as other products and services to this market segment."
The incidence of skin cancer has steadily increased over the past 75 years. During the 1930s, 1 in 1500 developed skin cancer. In 1960, the rate had risen to 1 in 600 and in 2000, the rate increased to 1 in 66. The National Cancer Institute estimates that 1 out of 5 is now at risk for developing some form